JP2014531020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531020A5 JP2014531020A5 JP2014533426A JP2014533426A JP2014531020A5 JP 2014531020 A5 JP2014531020 A5 JP 2014531020A5 JP 2014533426 A JP2014533426 A JP 2014533426A JP 2014533426 A JP2014533426 A JP 2014533426A JP 2014531020 A5 JP2014531020 A5 JP 2014531020A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- bin1
- seq
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 84
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 claims description 63
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 201000011510 cancer Diseases 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 239000013642 negative control Substances 0.000 claims description 12
- 239000012830 cancer therapeutic Substances 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 239000013641 positive control Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 6
- 208000003849 large cell carcinoma Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 208000000649 small cell carcinoma Diseases 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 4
- 102000001708 Protein Isoforms Human genes 0.000 claims description 4
- 108010029485 Protein Isoforms Proteins 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- 101000970561 Homo sapiens Myc box-dependent-interacting protein 1 Proteins 0.000 claims description 2
- 239000010425 asbestos Substances 0.000 claims description 2
- 102000053485 human BIN1 Human genes 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052895 riebeckite Inorganic materials 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 101710146921 Myc box-dependent-interacting protein 1 Proteins 0.000 description 35
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541539P | 2011-09-30 | 2011-09-30 | |
| US61/541,539 | 2011-09-30 | ||
| PCT/US2012/058051 WO2013049666A1 (en) | 2011-09-30 | 2012-09-28 | Bin1 expression as a marker of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531020A JP2014531020A (ja) | 2014-11-20 |
| JP2014531020A5 true JP2014531020A5 (enExample) | 2015-11-05 |
| JP6170925B2 JP6170925B2 (ja) | 2017-07-26 |
Family
ID=47023105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533426A Active JP6170925B2 (ja) | 2011-09-30 | 2012-09-28 | 癌のマーカーとしてのｂｉｎ１の発現 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9846159B2 (enExample) |
| EP (1) | EP2761298B1 (enExample) |
| JP (1) | JP6170925B2 (enExample) |
| CA (1) | CA2850178C (enExample) |
| WO (1) | WO2013049666A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013049666A1 (en) | 2011-09-30 | 2013-04-04 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| JP6742330B2 (ja) * | 2015-03-02 | 2020-08-19 | サーコーティン ダイアグノスティックス エルエルシー | 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現 |
| GB201600328D0 (en) * | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| US10766954B2 (en) * | 2016-04-06 | 2020-09-08 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| CN111868260B (zh) | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| CN113122636A (zh) * | 2020-01-14 | 2021-07-16 | 上海鹍远生物技术有限公司 | 检测dna甲基化的试剂及用途 |
| CN112794900B (zh) * | 2020-12-31 | 2022-10-25 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US6048702A (en) | 1995-05-05 | 2000-04-11 | The Wistar Institute Of Anatomy And Biology | Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor |
| US6410237B1 (en) | 1997-07-18 | 2002-06-25 | Board Of Trustees Operating Michigan State University | DNA encoding canine von Willebrand factor and methods of use |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| WO2001004354A2 (en) | 1999-07-07 | 2001-01-18 | Regeneron Pharmaceuticals, Inc. | Use of ras inhibitors of inhibiting muscle atrophy |
| US6831063B1 (en) * | 1999-08-31 | 2004-12-14 | The Wistar Institute Of Anatomy And Biology | Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor |
| US6461828B1 (en) | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
| US20040106954A1 (en) | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
| EP1631689A2 (en) | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US20040241764A1 (en) | 2003-06-02 | 2004-12-02 | Uri Galili | Early detection of recipient's immune response against heart transplant |
| US20090088482A1 (en) | 2003-10-14 | 2009-04-02 | The Trustees Of Columbia University In The City New York | Compositions and Methods For Treating Heart Failure |
| WO2005113798A2 (en) | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
| WO2006009629A2 (en) | 2004-06-10 | 2006-01-26 | New York University | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same |
| WO2006122295A2 (en) | 2005-05-11 | 2006-11-16 | Expression Diagnostics, Inc. | Methods of monitoring functional status of transplants using gene panels |
| WO2007130549A1 (en) | 2006-05-02 | 2007-11-15 | Govt.Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibody microarray |
| WO2008008846A2 (en) | 2006-07-11 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential expression of molecules associated with intra-cerebral hemorrhage |
| WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| US20120094300A1 (en) | 2009-04-24 | 2012-04-19 | Robin Shaw | Bin1 as a Prognostic Marker in Cardiovascular Disease |
| WO2011109806A2 (en) * | 2010-03-05 | 2011-09-09 | On-Q-ity | Biomarkers for the identification, monitoring, and treatment of non-small cell lung cancer (nsclc) |
| WO2012054764A1 (en) | 2010-10-20 | 2012-04-26 | The Regents Of The University Of California | Body fluid bin1 as a marker of cardiac health |
| EP2638403B1 (en) | 2010-11-09 | 2017-03-22 | Sarcotein Diagnostics LLC | Bin1 expression as a marker of skeletal muscle mass and neurological conditions |
| WO2013049666A1 (en) | 2011-09-30 | 2013-04-04 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| JP6742330B2 (ja) | 2015-03-02 | 2020-08-19 | サーコーティン ダイアグノスティックス エルエルシー | 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現 |
-
2012
- 2012-09-28 WO PCT/US2012/058051 patent/WO2013049666A1/en not_active Ceased
- 2012-09-28 CA CA2850178A patent/CA2850178C/en active Active
- 2012-09-28 JP JP2014533426A patent/JP6170925B2/ja active Active
- 2012-09-28 US US14/348,269 patent/US9846159B2/en active Active
- 2012-09-28 EP EP12773186.7A patent/EP2761298B1/en active Active
-
2017
- 2017-11-30 US US15/827,568 patent/US10928396B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531020A5 (enExample) | ||
| Gul et al. | Adjuvant therapy in renal cell carcinoma | |
| Ezzoukhry et al. | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib | |
| Maierthaler et al. | Plasma miR‐122 and miR‐200 family are prognostic markers in colorectal cancer | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Huang et al. | Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area | |
| JP2018508593A5 (enExample) | ||
| EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
| NZ584787A (en) | Inhibition of angiogenesis with a Bv8 antagonist | |
| EA201391587A1 (ru) | Комбинированная терапия на основе hsp90 | |
| JP2016020389A5 (enExample) | ||
| NO20092604L (no) | VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. | |
| Rostila et al. | Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| EA201390740A1 (ru) | Способ лечения с использованием ингибитора braf | |
| JP2013506675A5 (enExample) | ||
| JP2013539468A5 (enExample) | ||
| JP2015506944A5 (enExample) | ||
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| EA201201373A1 (ru) | Антитело, распознающее лейкемический ингибиторный фактор (lif) человека, и применение антител против lif при лечении заболеваний, связанных с нежелательной пролиферацией клеток | |
| JP2015508063A5 (enExample) | ||
| EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
| WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
| Gardini et al. | eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study | |
| BR102012006063A8 (pt) | Inibidor de met para uso no tratamento de um paciente sofrendo de um tumor, e, sequência de nucleotídeo |